Downstream Processing Featured Articles
-
Getting A Biotech Back On The Path Toward Commercialization
3/28/2012
There has been much debate as to how much it costs to get a new drug from discovery to market — anywhere from Light and Waburton’s 2011 estimate of R&D costs being in the neighborhood of $59.4M to PhRMA’s mind-numbing figure of $1.32B. By Rob Wright
-
Company Recognized For Outstanding Contributions To The Pharmaceutical Sciences
5/30/2012
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012 Excellence in Ligand Binding Assays Award to the Bioanalytical Development group from Morphotek for their abstract, “Development and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Phase II/III Clinical Studies.” The award was presented at the AAPS 2012 National Biotechnology Conference held May 21-23 in San Diego.
-
New Strategy Prevents Rheumatoid Arthritis In Mice
2/8/2013
Dana-Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model.
-
OHSU Doernbecher Scientists First To Grow Liver Stem Cells In Culture, Transplant Them With Demonstrated Therapeutic Benefit
2/25/2013
For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions.
-
AET BioTech And BioXpress Therapeutics To Co-Develop Biosimilar Adalimumab
10/30/2012
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
-
Novasep Launches The Sius Single-Use TFF Skid, Completing The First 100 Per Cent Single-Use TFF Solution For Pre-Clinical To Clinical cGMP Biomanufacturing
2/14/2013
Novasep, a leading supplier of purification solutions to the life sciences industries, recently announces the launch of its Sius single-use tangential flow filtration (TFF) skid.
-
Reconstruction Of Prehistoric DNA Refutes Criticism On Theory Of Evolution
12/10/2012
Scientists from VIB, KU Leuven, UGent and Harvard have succeeded in reconstructing DNA and proteins from prehistoric yeast cells. This made it possible to determine how genes developed and evolved into their current form over more than 100 million years.
-
MorphoSys And Heptares Sign Alliance To Develop Antibody Therapeutics Targeting GPCRs
2/13/2013
MorphoSys AG (Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.
-
Who’s Improving Bioprocessing In 2014?
1/6/2014
Last month we discussed the broad trends in innovation in bioprocessing that will shape the next five years. These include better single-use devices, assays, connectors and system integrations, and alternatives to chromatography. This month we drill down into areas where product innovators are actually investing in these improvements and technologies. Below is a sampling of key bioprocessing innovations. A thorough treatment would require an encyclopedia; this is an appetizer for what’s to come.
-
Success Of Engineered Tissue Depends On Where It’s Grown
8/14/2012
Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others. By Anne Trafton